NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 15 மணி நேரத்திற்கு முன்இன்று 91 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Suraksha Diagnostic Reports Q2 FY27 PAT Growth of 69% YoY to ₹14.95 Cr in Investor Presentation
Suraksha Diagnostic issued its Q2 & H1 FY27 investor presentation ahead of its earnings call on November 13, 2026. For Q2 FY27, total revenue rose 26.4% YoY to ₹100.58 Cr (from ₹79.58 Cr in Q2 FY26), while consolidated PAT increased 69.3% YoY to ₹14.95 Cr. Operating performance strengthened with EBITDA growing 45.5% YoY to ₹36.32 Cr and EBITDA margins expanding 500 bps to 36.7%. The company expanded its network to 77 centres, adding 5 new centres (2 hubs, 3 spokes) during the quarter.
உச்சம் நம்பிக்கை
என்ன மாறியதுSuraksha Diagnostic published its detailed Q2 & H1 FY27 financial performance and operating presentation ahead of its earnings call.
ஏன் இது முக்கியம்Demonstrates strong operating leverage with EBITDA margins expanding to 36.7% and revenue per patient increasing to ₹2,348, supporting ongoing regional centre network expansion.
📅 குறுகிய காலம்Positive sentiment likely on healthy double-digit revenue growth and strong margin expansion reported for the quarter.
📈 நீண்ட காலம்Sustained revenue growth depends on the successful ramp-up of immature centres and expansion of high-margin specialised segments like genomics.
⚠ அபாய எச்சரிக்கைகள்
Geographic concentration in Eastern India/West Bengal
Pricing competition from pan-India diagnostic players
👀 கவனிக்க வேண்டியவை
Track management commentary during the earnings call on November 13, 2026, regarding expansion beyond West Bengal and the maturation pace of the 15+ immature centres.
Suraksha Diagnostic Q2 PAT Surges 69% YoY to ₹14.95 Cr; EBITDA Margin Expands to 36.7%
Suraksha Diagnostic reported strong Q2 FY27 operational and financial results, with Total Income rising 26% YoY to ₹100.58 Cr (₹1,005.75 mn) and PAT expanding 69% YoY to ₹14.95 Cr (₹149.50 mn). EBITDA jumped 45% YoY to ₹36.32 Cr with margins widening 500 bps to 36.7%. Growth was driven by an expanding network—adding 5 new centers in the quarter—and higher realization, with Average Revenue Per Test rising 19% YoY to ₹427. For H1 FY27, Total Income grew 24% to ₹189.31 Cr, while PAT grew 54% to ₹27.80 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுSuraksha Diagnostic released its Q2 and H1 FY27 earnings press release showing accelerated revenue growth and robust margin expansion.
ஏன் இது முக்கியம்Demonstrates operating leverage from maturing centers and network expansion, significantly outperforming historic annual PAT growth.
Suraksha Diagnostic Limited's Board of Directors met on November 10, 2026, and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026. The meeting commenced at 03:00 PM IST and concluded at 03:40 PM IST. The detailed financial statements and Limited Review Report issued by statutory auditors are included under Annexure-A. The company has a market cap of Rs 1,786 Cr and TTM revenue of Rs 325 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுFormal approval and submission of Unaudited Financial Results for the period ended September 30, 2026.
ஏன் இது முக்கியம்Provides investors with quarterly diagnostic operational performance and updates on post-monsoon patient volumes in Eastern India.
Meeting Date: 10th நவம்பர், 2026Meeting Duration: 40 minutes (03:00 PM to 03:40 PM IST)சந்தை மதிப்பு: Rs 1786 கோடி
📅 குறுகிய காலம்Market focus will shift to reading the detailed numbers in Annexure-A to gauge margin impact and volume recovery following Q2 seasonal factors.
📈 நீண்ட காலம்Limited from this procedural outcome filing; long-term trajectory depends on expanding store count across Eastern India and genomics scale-up.
⚠ அபாய எச்சரிக்கைகள்
Detailed P&L figures not included in the main body text of the filing extract
👀 கவனிக்க வேண்டியவை
Review the detailed Annexure-A financial figures (revenue, EBITDA, and PAT margins) once published to assess H1 FY27 performance against the historical TTM revenue run-rate of Rs 325 Cr.
Suraksha Diagnostic Q1 FY27 Transcript: Revenue Up 21% YoY, PAT Jumps 40% to ₹12.8 Cr
Suraksha Diagnostic released its Q1 FY27 earnings call transcript, reporting a 21% YoY rise in total income to INR 88.7 cr and a 40% YoY jump in PAT to INR 12.8 cr. Network count reached 72 centres, with immature centres (<2 years old) turning EBITDA positive at 6.5% versus -5.5% in the prior quarter. The company is actively expanding beyond West Bengal into Jharkhand and Tripura, with plans to add ~20 labs in FY27. Specialized testing arm Suraksha Genomics grew 136% YoY to INR 1.37 cr, marking five consecutive quarters of sequential growth.
உச்சம் நம்பிக்கை
என்ன மாறியதுSuraksha Diagnostic published the transcript of its Q1 FY27 earnings call detailing regional expansion plans and margin drivers.
ஏன் இது முக்கியம்Shows operational leverage playing out as younger centres turn profitable and regional diversification beyond West Bengal gains traction.
📅 குறுகிய காலம்Strong operational momentum and profitability in young centers support stable near-term performance.
📈 நீண்ட காலம்Geographic diversification across Eastern and Northeastern India and scale in high-value genomics panels could drive sustained margin expansion.
⚠ அபாய எச்சரிக்கைகள்
Moderation in test volume growth pace to 10-11% compared to >20% in preceding quarters
Execution and brand acceptance risks in newly entered non-core geographies like Jharkhand and Tripura
👀 கவனிக்க வேண்டியவை
Track the execution and utilization ramp-up of new centres in Jharkhand and Tripura, alongside monitoring volume growth trends in routine pathology.
40% PAT Growth in Q1 FY27; Suraksha Diagnostic Reports Margin Expansion to 36%
Suraksha Diagnostic reported a strong start to FY27 with total income rising 21% YoY to ₹88.7 Cr. Profitability significantly outperformed revenue growth, with PAT increasing 40% to ₹12.8 Cr and EBITDA margins expanding by 200 bps to 36.0%. Operational efficiency improved as Average Revenue per Patient (ARPP) grew 10.5% to ₹2,321, despite a slight 2.8% dip in tests per patient. The company continued its expansion by adding 1 hub and 3 spoke centers during the quarter.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company achieved a significant margin expansion and strong bottom-line growth, driven by higher realizations per patient and rapid growth in specialized genomics testing.
ஏன் இது முக்கியம்The results demonstrate the company's ability to improve profitability through a better product mix (Genomics) and higher realizations, even while continuing its physical network expansion in Eastern India.
Q1 FY27 Total Income: ₹887 millionQ1 வருவாய் vs TTM வருவாய்: ~28.6%EBITDA லாப வரம்பு: 36.0%PAT Growth (YoY): 40.0%Genomics Revenue Growth: 136%Average Revenue per Patient: ₹2,321
📅 குறுகிய காலம்The stock may react positively to the strong margin expansion and 40% PAT growth, which exceeds the TTM growth trajectory.
📈 நீண்ட காலம்Structural growth remains tied to the successful ramp-up of 12-15 new centers annually and the transition towards high-margin specialized diagnostics like Genomics and prenatal care.
⚠ அபாய எச்சரிக்கைகள்
Intense competition in West Bengal from pan-India diagnostic players
Potential impact of seasonal weather/floods on patient mobility in Eastern India
👀 கவனிக்க வேண்டியவை
Investors should monitor the margin sustainability as the company scales its 15 immature centers and tracks the revenue contribution from the high-margin Genomics segment.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Suraksha Diagnostic Sets Sept 15 Dividend Record Date; Appoints New Group CFO
Suraksha Diagnostic reported standalone revenue of ₹84.09 Cr for Q1 FY27, representing a sequential growth of 6.7% over the March 2026 quarter. The board has fixed September 15, 2026, as the record date for the FY26 dividend, with the AGM scheduled for September 22. Additionally, Mr. Dinesh Gupta has been appointed as the Group Chief Financial Officer effective August 24, 2026. The company maintained a standalone net profit of ₹12.58 Cr for the quarter ended June 30, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has finalized its Q1 FY27 financial results, scheduled its annual shareholder meeting, and transitioned its financial leadership with a new CFO appointment.
ஏன் இது முக்கியம்The appointment of a new CFO is significant as the company executes its 15% growth strategy and expansion into high-margin segments like genomics. The Q1 results indicate steady revenue momentum relative to the TTM average.
Q1 FY27 Standalone Revenue: ₹84.09 கோடிQ1 FY27 Standalone PAT: ₹12.58 கோடிDividend Record Date: 15-செப்.-2026CFO Appointment Date: 24-ஆக.-2026Q1 வருவாய் vs TTM வருவாய்: 27.1%
📅 குறுகிய காலம்The stock may see routine activity around the dividend record date and the market's assessment of the Q1 earnings performance.
📈 நீண்ட காலம்Long-term value depends on the successful scaling of the 33% currently immature centers and the integration of the Fetomat acquisition to boost margins.
⚠ அபாய எச்சரிக்கைகள்
Management transition risk (New CFO)
Intense competition in West Bengal pathology market
Dependency on reagent suppliers
👀 கவனிக்க வேண்டியவை
Investors should track the transition to the new CFO and monitor the upcoming AGM for updates on the company's plan to add 12-15 new centers in FY26.
Suraksha Diagnostic Appoints Dinesh Gupta as CFO; Q1 FY27 PAT Rises 37% to ₹12.58 Cr
Suraksha Diagnostic reported a strong start to FY27 with Q1 revenue reaching ₹84.08 Cr, a 15.8% increase over the ₹72.59 Cr reported in Q1 FY26. Net profit for the quarter surged 37% YoY to ₹12.58 Cr, driven by improved operational efficiencies. The board has appointed Mr. Dinesh Gupta, a Chartered Accountant with 14 years of experience, as the new Group CFO effective August 24, 2026. Additionally, the company fixed September 15, 2026, as the record date for the FY26 dividend payment.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned its financial leadership to Mr. Dinesh Gupta and reported double-digit growth in both top-line and bottom-line for the first quarter of FY27.
ஏன் இது முக்கியம்Strong Q1 results validate the company's 15% growth target and its ability to scale in the competitive Eastern India market. The appointment of a seasoned CFO is critical for managing the planned 30% increase in store count.
Q1 FY27 Revenue: ₹84.08 கோடிQ1 FY27 PAT: ₹12.58 கோடிYoY PAT Growth: 37.1%CFO Experience: 14 yearsDividend Record Date: செப்டம்பர் 15, 2026
📅 குறுகிய காலம்The stock may see positive momentum following the 37% PAT growth and the announcement of the dividend record date.
📈 நீண்ட காலம்The company's focus on high-margin segments like Genomics and its aggressive center expansion (12-15 annually) remain the primary structural growth drivers.
⚠ அபாய எச்சரிக்கைகள்
Intense competition in West Bengal from pan-India diagnostic chains
Execution risk in scaling 15 centers that are currently less than one year old
👀 கவனிக்க வேண்டியவை
Watch for the new CFO's impact on cost management as the company executes its plan to add 12-15 new centers in FY27. Investors should also note the dividend record date of September 15 for entitlement.
Suraksha Diagnostic FY26 Revenue Up 23% to ₹310 Cr; EBITDA Margins Steady at 31.7%
Suraksha Diagnostic Limited reported a robust 23.1% YoY increase in FY26 revenue to INR 3,104.1 million, driven by higher volumes and a premium test mix. EBITDA margins remained strong at 31.73%, although full-year PAT growth was limited to 1.4% at INR 314 million due to increased depreciation and finance costs from network expansion. The company expanded its footprint to 68 centers and plans to enter Bihar, Jharkhand, and Tripura in FY27. Revenue per patient improved to INR 2,264, reflecting a strategic shift toward high-end radiology and genomics.
முக்கிய அம்சங்கள்
FY26 Revenue grew 23.1% YoY to INR 3,104.1 million with a 3-year CAGR of 17.78%.EBITDA margin for the year stood at 31.73%, while mature centers achieved 36-37%.Total patient count reached 1.37 million with a significant volume of 8.16 million tests.Network expanded to 68 centers, with plans to add 3 hubs and 8 spokes in West Bengal in FY27.Revenue per patient increased to INR 2,264, supported by advanced radiology and genomics.
👀 கவனிக்க வேண்டியவை
Investors should monitor the margin trajectory as new centers in Bihar and Jharkhand scale up. The company's strong presence in Eastern India and high-end diagnostic capabilities provide a solid long-term growth outlook.
Suraksha Diagnostic FY26 Income up 23% to ₹3,136M; Q4 EBITDA Grows 26% YoY
Suraksha Diagnostic reported a robust 23% YoY growth in total income for FY26, reaching ₹3,136 million, supported by a 22% increase in test volumes. While full-year PAT remained nearly flat at ₹314 million (+1.4%) due to aggressive expansion costs, Q4 FY26 showed strong operational momentum with EBITDA rising 25.7% YoY. The company added 17 new facilities (hubs, spokes, and PPPs) during the year, which temporarily compressed margins. Management noted that mature centers (over 2 years old) maintain high EBITDA margins of 36-37%, indicating significant upside as new centers scale.
முக்கிய அம்சங்கள்
Total Income for FY26 increased by 23% YoY to ₹3,136 million, with Q4 FY26 income up 24.7% to ₹822 million.FY26 EBITDA grew 16% YoY to ₹986 million, though Q4 FY26 EBITDA showed a stronger growth of 25.7% YoY.Total test volumes grew 22% YoY in FY26 to 8.16 million, while Q4 Average Revenue Per Patient (ARPP) surged 23% to ₹2,706.Network expansion included the addition of 2 hubs, 11 spoke centres, and 4 PPP projects during the financial year.Mature centers (>2 years old) are operating at stable EBITDA margins of 36-37%.
👀 கவனிக்க வேண்டியவை
Investors should focus on the volume growth and the scaling of the 17 newly added centers, as their maturation is the primary catalyst for margin expansion. The stock remains a growth play in the East Indian diagnostic market, with the current PAT compression being a result of strategic long-term capacity building.
Suraksha Diagnostic FY26 Revenue Grows 23% to ₹3,136M; Network Expands to 68 Centres
Suraksha Diagnostic Limited reported a robust 23% YoY revenue growth for FY26, reaching ₹3,136 million, driven by volume growth and network expansion in Eastern India. While EBITDA grew 16% to ₹986 million, PAT remained nearly flat at ₹314 million due to higher depreciation and finance costs associated with adding 20 new centres since listing. A key highlight is the performance gap between mature centres (36.5% EBITDA margin) and newer centres (-5.5% EBITDA margin), indicating significant margin expansion potential as the new units scale up.
முக்கிய அம்சங்கள்
FY26 Revenue increased 23% YoY to ₹3,136 million, with Q4 FY26 revenue up 25% to ₹822 million.EBITDA for FY26 stood at ₹986 million with a 31.8% margin, though Q4 margins improved to 30.9% compared to the previous quarter.The company served 1.37 million patients and performed 8.16 million tests in FY26, with a high B2C revenue contribution of 89%.Network expanded to 68 diagnostic centres and 193 collection centres, with 20 centres added since the December 2024 listing.Mature centres (>2 years old) maintained strong profitability with EBITDA margins between 36-37%.
👀 கவனிக்க வேண்டியவை
Investors should focus on the 'maturation curve' of the 26 new centres; as these transition from -5.5% to the company's mature 36% margin profile, earnings are expected to accelerate. The stock remains a strong regional play in the Eastern Indian diagnostic market with high B2C stickiness.
Suraksha Diagnostic reported a strong performance for FY26, with annual revenue from operations increasing by 20.7% to ₹30,067.91 lakhs compared to the previous year. The Board has recommended a final dividend of ₹0.50 per equity share (25% of face value) for the financial year. For the quarter ended March 31, 2026, revenue stood at ₹7,855.59 lakhs, showing healthy year-on-year growth from ₹6,414.51 lakhs. The company also announced the appointment of new internal auditors and fixed August 26, 2026, as the record date for the dividend.
முக்கிய அம்சங்கள்
Annual revenue from operations grew 20.7% YoY to ₹30,067.91 lakhs in FY26Q4 FY26 revenue increased to ₹7,855.59 lakhs from ₹6,414.51 lakhs in the same quarter last yearRecommended a final dividend of ₹0.50 per share (25% on face value of ₹2)Total income for FY26 reached ₹30,503.14 lakhs compared to ₹25,347.84 lakhs in FY25Record date for dividend entitlement set for August 26, 2026
👀 கவனிக்க வேண்டியவை
Investors should note the steady double-digit revenue growth and the consistent dividend payout. The stock remains a key player to watch within the diagnostic sector, particularly for its regional dominance in Eastern India.
Suraksha Diagnostic Group CFO K S Ravindra Resigns Effective May 31, 2026
Suraksha Diagnostic Limited has announced the resignation of Mr. K S Ravindra from the post of Group Chief Financial Officer (CFO) and Key Managerial Personnel (KMP). The resignation was tendered on March 2, 2026, citing personal reasons, with his tenure concluding on May 31, 2026. The company has initiated a three-month notice period to ensure a smooth transition of financial responsibilities. No material reasons other than personal ones were cited for the departure.
முக்கிய அம்சங்கள்
Mr. K S Ravindra resigned as Group CFO and KMP on March 2, 2026The resignation is effective from the close of business hours on May 31, 2026A 3-month notice period is being served to facilitate a smooth leadership transitionThe outgoing CFO confirmed there are no material reasons for resignation other than personal ones
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's upcoming announcements regarding the appointment of a new CFO to ensure continuity in financial management. The three-month notice period provides a reasonable window for a stable transition.
Suraksha Diagnostic Q3 Revenue Jumps 30% YoY to ₹78.3 Cr; EBITDA Margins at 30.6%
Suraksha Diagnostic reported a strong 30.3% YoY increase in Q3 FY26 revenue to INR 783.09 million, driven by volume expansion and a shift towards high-value genomic testing. While EBITDA grew 26.1% to INR 237.82 million, margins saw a temporary compression to 30.6% due to pre-operative costs associated with 24 new centers. The company served 0.36 million patients in Q3, a 23% increase, while the total number of tests performed rose by 30.7% to 2.06 million. Management revised EBITDA margin guidance slightly downward to approximately 32% for the full year, citing aggressive network expansion and seasonal weakness.
முக்கிய அம்சங்கள்
Q3 FY26 revenue grew 30.3% YoY to INR 783.09 million, with 9M FY26 revenue up 21.86% to INR 2,313.81 millionEBITDA margin for Q3 stood at 30.6%, impacted by 24 new centers, while 42 mature centers maintain robust profilesThe new genomics vertical Suraksha Sutra is generating a monthly revenue run rate of approximately INR 2.1-2.2 millionThe company remains net debt positive with a cash position of approximately INR 29 crores as of the reporting dateExpansion continues with 12 centers commissioned in 9 months and 6 more facilities currently in the execution phase
👀 கவனிக்க வேண்டியவை
Investors should focus on the successful ramp-up of new centers and the high-margin genomics vertical, which act as long-term growth drivers despite short-term margin compression. Monitor the stabilization of EBITDA margins as the 24 new centers reach maturity over the next 12-18 months.
Suraksha Diagnostic Q3 Revenue Jumps 30% to ₹783 Mn; Mature Center Margins Hit 36.2%
Suraksha Diagnostic reported a robust 30.3% YoY revenue growth in Q3 FY26, reaching ₹783.09 million, driven by aggressive network expansion. While overall EBITDA margins compressed slightly to 30.6% due to pre-operative costs of 24 new centers, mature centers (over 2 years old) continue to deliver strong margins of 36.2%. The company is diversifying into high-value segments like Genomics and Fetal medicine to increase revenue per patient, which rose to ₹2,140. Management remains focused on 'Investing for Scale,' with 6 more centers planned for launch in Q4 FY26.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue increased 30.3% YoY to ₹783.09 million, while PAT grew 21% to ₹72.41 million.Mature centers (42 units) operate at a 36.2% EBITDA margin, while 24 new centers are currently at -12.5% during their gestation period.Total network reached 66 diagnostic centers and 173 collection centers as of December 31, 2025.Revenue per patient improved to ₹2,140 in 9M FY26, supported by the launch of the high-margin Suraksha Genomics vertical.EBITDA for 9M FY26 stood at ₹734.04 million, representing a 12.8% YoY growth despite heavy investment in expansion.
👀 கவனிக்க வேண்டியவை
Investors should monitor the margin trajectory as the 24 recently opened centers mature; their shift toward the 36% margin profile of established centers will be the primary driver for future earnings upgrades. The successful scaling of the specialized Genomics vertical remains a key long-term catalyst for valuation re-rating.
Suraksha Diagnostic Q3 FY26 Income Up 30.3% to ₹783M; Test Volumes Surge 30.7%
Suraksha Diagnostic Limited reported robust Q3 FY26 results with total income rising 30.3% YoY to ₹783.09 million. Net profit increased by 21% to ₹72.41 million, while EBITDA grew 26.1% to ₹237.82 million. The company witnessed significant volume growth with total tests increasing by 30.7% YoY to 2.06 million. Although EBITDA margins compressed slightly to 30.6% due to aggressive expansion, mature centers continue to deliver strong 37% margins.
முக்கிய அம்சங்கள்
Total Income grew 30.3% YoY to ₹783.09 million in Q3 FY26.EBITDA increased by 26.1% YoY to ₹237.82 million with a 30.6% margin.Total test volume rose 30.7% YoY to 2.06 million; patients served grew 23% to 0.36 million.Average Revenue per Patient (ARPP) increased 6.1% YoY to ₹2,181.Added 12 new centers in 9M FY26 with 6 more currently under development.
👀 கவனிக்க வேண்டியவை
The stock remains attractive due to strong volume growth and the high-margin potential of mature centers (37%). Investors should watch for margin recovery as the 12 newly added centers scale up over the next 12-18 months.
Suraksha Diagnostic Q3 FY26 Standalone PAT Rises to ₹9.75 Crore, Income Up 20% YoY
Suraksha Diagnostic Limited reported a steady growth in its standalone operations for the quarter ended December 31, 2025. Total standalone income reached ₹58.30 crore, representing a 20.7% increase compared to the ₹48.29 crore reported in the same quarter last year. Standalone Net Profit for the quarter stood at ₹9.75 crore, while consolidated performance was slightly impacted by losses in subsidiaries totaling ₹0.91 crore. The company is also managing a legal dispute in Meghalaya involving ₹4.35 crore in receivables and investments.
முக்கிய அம்சங்கள்
Standalone Total Income grew 20.7% YoY to ₹58.30 crore from ₹48.29 crore in Q3 FY25.Standalone Profit After Tax (PAT) for Q3 FY26 stood at ₹9.75 crore with an EPS of ₹1.25.Consolidated subsidiaries contributed ₹2.83 crore in revenue but reported a net loss of ₹0.91 crore for the quarter.Nine-month (9M FY26) standalone total income reached ₹163.30 crore compared to ₹143.30 crore in the previous year.Management is monitoring a ₹4.35 crore dispute regarding a step-down subsidiary's operations in Meghalaya.
👀 கவனிக்க வேண்டியவை
The core standalone diagnostic business shows robust double-digit growth and healthy profitability. Investors should monitor the turnaround of loss-making subsidiaries and the resolution of the Meghalaya legal dispute which involves significant receivables.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
